Physician profile
Emily Jensen
NPI 1497030118
$1,238.47
in general payments reported to CMS, 2019-2025
16 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.21 · 2022: $405 · 2023: $590 · 2024: $75.24 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.13 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $173.81 | 2022-2023 | Livalo, Seglentis |
| Biohaven Pharmaceutical Holding Company Ltd. | $124.91 | 2022 | |
| Pfizer INC. | $86.33 | 2023 | |
| Lilly USA, LLC | $74.12 | 2022-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.60 | 2025 | Xifaxan |
| Genentech USA, INC. | $62.21 | 2021 | |
| Novo Nordisk INC | $60.33 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $48.16 | 2023 | Farxiga, Fasenra |
| Amgen INC. | $40.52 | 2022-2023 | Repatha, Otezla |
| Phadia US INC. | $32.37 | 2023 | Immunocap |
| Acella Pharmaceuticals, LLC | $19.41 | 2025 | NP Thyroid 60 |
| Astellas Pharma US INC | $17.21 | 2023 | Myrbetriq |
| Ibsa Pharma INC. | $16.21 | 2025 | Flector, Tirosint, Licart |
| Sunovion Pharmaceuticals INC. | $13.29 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.